Dexamethasone therapy and rates of secondary pulmonary and bloodstream infections in critically ill COVID-19 patients.

Kathrin Rothe,Tobias Lahmer,Sebastian Rasch,Jochen Schneider,Christoph D Spinner,Fabian Wallnöfer,Milena Wurst,Roland M Schmid,Birgit Waschulzik,Kristina Fuest,Silja Kriescher,Gerhard Schneider,Dirk H Busch,Susanne Feihl,Markus Heim

Multidisciplinary respiratory medicine（2021）

引用 12|浏览15

暂无评分

摘要

Secondary infections are present in a substantial fraction of critically ill COVID-19 patients. Respiratory pathogens were detectable in the majority of COVID-19 ICU patients. The use of dexamethasone poses a potential risk of secondary pulmonary infections. Infectious complications in patients with dexamethasone therapy could be associated with worse outcomes.

查看译文

关键词

COVID-19,SARS-CoV-2,antibiotic stewardship,bacterial infection,critical care,dexamethasone

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要